Molecular Diagnostics News and Research

RSS

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.

21 Mar 2011

Quest Diagnostics enters definitive merger agreement to acquire Celera for $8 per share

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, and Celera Corporation, one of the world's pioneers in genetic diagnostics discovery and development, announced today that they have entered into a definitive merger agreement under which Quest Diagnostics will acquire Celera for $8 per share, representing a transaction value of approximately $344 million, net of $327 million in acquired cash and short-term investments.

From Quest Diagnostics 18 Mar 2011

Quest Diagnostics ColoVantage molecular colorectal cancer detection test receives New York State approval

Quest Diagnostics Incorporated, the world's leading cancer diagnostics company, today announced that its ColoVantage test has been approved by New York State's Department of Health for testing on samples of patients in the state. It is believed to be the first molecular colorectal cancer detection method that employs a venal blood specimen to be approved by the state.

From Quest Diagnostics 18 Mar 2011

Ambry, LABS partner to offer new donor and patient screening options

LABS, Inc., the recognized leader in microbiology, infectious disease screening, cell/molecular biology and immunological testing for the transplant and biomedical sciences communities, today announced an agreement with Ambry Genetics, a global leader in molecular diagnostics and genomic services to the healthcare and life sciences industries, that will allow the organizations to provide superior testing services to a broader base of clients in the reproductive health industry.

16 Mar 2011

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

Vermillion, a molecular diagnostics company, today announced the presentation of positive preliminary data from its collaboration with Johns Hopkins University School of Medicine to identify biomarkers that improve on the specificity of CA125 for the identification of malignant ovarian tumors.

9 Mar 2011

ADC announces RNAscope technology clinical study results for HPV-associated head and neck cancers

Advanced Cell Diagnostics, Inc. today announced the results of its clinical study utilizing RNAscope technology to detect human papillomavirus E6/E7 mRNA in routine clinical specimens of head and neck cancer.

From Advanced Cell Diagnostics 1 Mar 2011

Renishaw launches first RUO multiplex assay system

Renishaw Diagnostics Ltd, a world leading provider of trace level detection technologies based on the exploitation of surface enhanced Raman scattering and surface enhanced resonance Raman scattering, for research and molecular diagnostics applications, today announced the launch of its first research use only multiplex assay system which allows precious research samples to be 'screened' for 10 or more 'targets', from a single sample.

1 Mar 2011

QIAGEN, Epigenomics enter option agreement to commercialize colorectal cancer blood test

Epigenomics AG, the cancer molecular diagnostics company, and QIAGEN today announced that the companies have entered into an option agreement allowing QIAGEN to develop and, should QIAGEN exercise the option, commercialize a colorectal cancer blood test based on Epigenomics' proprietary biomarker mSEPT9 and certain DNA methylation analysis technologies.

From QIAGEN Manchester Limited 28 Feb 2011

Biomatrica announces strategic partnership agreement with In-Q-Tel

Biomatrica, Inc., a leader in room temperature biostability technology, today announced a strategic partnership agreement with In-Q-Tel. IQT is the independent, strategic investment firm that identifies innovative technology solutions to support the mission of the U.S. Intelligence Community.

24 Feb 2011

CompanDX, CRL enter multi-year agreement to develop biomarker panels

CompanDX Ltd., bioinformatics partner for the life sciences industry, and Clinical Reference Laboratory, Inc. (CRL), provider of laboratory testing services in molecular diagnostics and clinical trials, today announced they entered into a multi-year agreement to collaborate in the development and support of biomarker panels and companion diagnostic development for pharmaceutical, biotech and academic clients worldwide.

19 Feb 2011

Partners, Luminex team up to discover novel biomarkers, develop clinical assays

Luminex Corporation announced today that it has teamed with Partners HealthCare toward the discovery of novel biomarkers and development of clinical assays.

From Luminex 16 Feb 2011

Akonni signs license agreement with USAMRIID to develop multiplex testing products for bio-security applications

Akonni Biosystems, a molecular diagnostics (MDx) company that develops rapid, low-cost and highly scalable solutions for infectious disease testing, today announced it has signed a license agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

10 Feb 2011

Breakthrough in Thermal Gradient's fast PCR technology for molecular diagnostics

Thermal Gradient, a Rochester, NY biotech company, announces a breakthrough in its fast PCR technology for molecular diagnostics. PCR is the preferred critical step in virtually all forms of DNA testing.

8 Feb 2011

XDx and LabCorp enter non-hospital provider agreement for AlloMap molecular expression tests

XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that it has entered into a multi-year agreement with Laboratory Corporation of America Holdings to provide heart transplant patients eligible for XDx's AlloMap® test with the convenience of having their blood drawn at participating LabCorp sites across the United States.

7 Feb 2011

Roche launches cobas TaqScreen DPX Test for parvovirus B19 and hepatitis A virus

Roche announced today that the cobas® TaqScreen DPX Test for use on the cobas s 201 system is now available in the US. It is the first commercial test to quantify parvovirus B19 and detect hepatitis A virus (HAV) simultaneously in one assay in human plasma.

5 Feb 2011

Metamark announces Nature journal published landmark prostate cancer study results

Metamark Genetics, Inc., a privately-held oncology molecular diagnostics company, today announced results from a landmark prostate cancer study published as an Advance Online Publication in the journal Nature.

3 Feb 2011

USPTO issues notice of allowance to Vermillion's breast cancer biomarkers

Vermillion, a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company.

2 Feb 2011

DNA Direct implements four new health plan clients for molecular diagnostic and genetic tests

DNA Direct, a wholly owned subsidiary of Medco Health Solutions, Inc. and a provider of guidance and decision support for genomic medicine, today announced four new health plan clients that are implementing DNA Direct's Policy & Benefit Support Program for molecular diagnostic and genetic tests.

1 Feb 2011

GE Capital provides capital to XDx to help increase commercialization of AlloMap molecular diagnostic test

GE Capital, Healthcare Financial Services announced today that it has provided, as sole lender, a $12.5 million senior secured multi-draw term loan facility to XDx, Inc. The financing provides XDx with working capital to expand the commercialization of its FDA-cleared, innovative, noninvasive AlloMap molecular diagnostic test and pursue the development of other gene expression-based tests for autoimmune diseases including lupus.

29 Jan 2011

XDx establishes $12.5 million multi-draw term loan facility with GE Capital

XDx, a San Francisco-based molecular diagnostics company focused on non-invasive gene expression-based tests for the monitoring of organ transplant rejection and autoimmune diseases, announced today that it has established a $12.5 million senior secured multi-draw term loan facility with GE Capital, Healthcare Financial Services.

28 Jan 2011